AstraZeneca Wins FDA Approval for New Bipolar Disorder Drug
Posted on: Monday, 13 October 2008, 09:00 CDT
AstraZeneca has received the FDA's approval for once-daily Seroquel extended-release tablets for the acute treatment of the depressive episodes associated with bipolar disorder, the manic and mixed episodes associated with bipolar I disorder, and the maintenance treatment of bipolar I disorder as adjunctive therapy to lithium or divalproex.
Seroquel extended-release (XR) is said to be the first medication approved by the FDA for the once-daily acute treatment of both depressive and manic episodes associated with bipolar disorder.
AstraZeneca submitted two separate supplemental new drug applications to the FDA to seek approval for these indications. The bipolar depression submission was supported by a clinical study of treatment with Seroquel XR compared with placebo in 280 patients diagnosed with bipolar depression. The primary endpoint was change from baseline in Montgomery-Asberg Depression Rating Scale total score compared to placebo at week eight.
The bipolar mania submission was based on a clinical study of treatment with Seroquel XR compared with placebo in 316 patients with bipolar mania or mixed episodes with or without psychotic features. The primary endpoint was change from baseline in Young Mania Rating Scale total score compared to placebo at week three.
Lisa Schoenberg, vice president of specialty care at AstraZeneca, said: "These new indications for Seroquel XR mark an important milestone in the treatment of bipolar disorder. In addition to today's approval for the treatment of both the depressive and manic symptoms associated with this condition, Seroquel XR is now also approved as a long-term treatment option for bipolar I disorder."
Source: Datamonitor
Related Articles
- Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
- ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
- Intent-to-Treat Analysis of Double-Blind Methamphetamine Study Confirms Hythiam's PROMETA Treatment Program Showed Statistically Significant Reduction in Cravings Compared to Placebo
- SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
- TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated With Schizophrenia
- FDA Approves Norditropin(R)for Treatment of Short Stature Associated With a Rare Genetic Disorder
- ABILIFY(R) (Aripiprazole) Demonstrated Efficacy As Long-Term Maintenance Therapy in Adults With Bipolar I Disorder Following Treatment for a Recent Manic Or Mixed Episode
- ABILIFY(R) (Aripiprazole) Demonstrated Efficacy As Maintenance Therapy In Adults With Bipolar I Disorder Following Treatment for a Recent Manic or Mixed Episode
- Optimer's Lead Antibiotic Candidate Moves Into Phase 2B/3 Clinical Trials for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
- New Study Showed No Difference in Total Treatment Costs When Comparing Those Starting Treatment With Older Conventional Antipsychotics and Those Starting Treatment With Zyprexa(R), an Atypical Antipsychotic, in the Treatment of Schizophrenia
 |
 |
User Comments (0)
RSS Feeds